The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID

Safavi S, Larouche A, Zahn A, Patenaude AM, Domanska D, Dionne K, Rognes T, Dingler F, Kang SK, Liu Y, Johnson N, Hébert J, Verdun RE, Rada CA, Vega F, Nilsen H, Di Noia JM. The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID. NAR Cancer. 2020 Aug 27;2(3):zcaa019. doi: 10.1093/narcan/zcaa019. Erratum in: NAR Cancer. 2021 Jan 06;3(1):zcaa045. PMID: 33554121; PMCID: PMC7848951.

An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics

Bern M, Nilsen J, Ferrarese M, Sand KMK, Gjølberg TT, Lode HE, Davidson RJ, Camire RM, Bækkevold ES, Foss S, Grevys A, Dalhus B, Wilson J, Høydahl LS, Christianson GJ, Roopenian DC, Schlothauer T, Michaelsen TE, Moe MC, Lombardi S, Pinotti M, Sandlie I, Branchini A, Andersen JT (2020). An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Sci Transl Med, 12 (565). PubMed 33055243 DOI 10.1126/scitranslmed.abb0580

CD4+ T cells persist for years in the human small intestine and display a TH1 cytokine profile

Bartolomé-Casado R, Landsverk OJB, Chauhan SK, Sætre F, Hagen KT, Yaqub S, Øyen O, Horneland R, Aandahl EM, Aabakken L, Bækkevold ES, Jahnsen FL (2020). CD4+ T cells persist for years in the human small intestine and display a TH1 cytokine profile. Mucosal Immunol, 14 (2), 402-410. PubMed 32572129 DOI 10.1038/s41385-020-0315-5

Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease

Divito SJ, Aasebø AT, Matos TR, Hsieh PC, Collin M, Elco CP, O’Malley JT, Bækkevold ES, Reims H, Gedde-Dahl T, Hagerstrom M, Hilaire J, Lian JW, Milford EL, Pinkus GS, Ho VT, Soiffer RJ, Kim HT, Mihm MC, Ritz J, Guleria I, Cutler CS, Clark RA, Jahnsen FL, Kupper TS (2020). Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest, 130 (9), 4624-4636. PubMed 32516138 DOI 10.1172/JCI129965

Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial

Fretheim H, Chung BK, Didriksen H, Bækkevold ES, Midtvedt Ø, Brunborg C, Holm K, Valeur J, Tennøe AH, Garen T, Midtvedt T, Trøseid M, Zarè H, Lund MB, Hov JR, Lundin KEA, Molberg Ø, Hoffmann-Vold AM (2020). Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial. PLoS One, 15 (5), e0232739. PubMed 32437393 DOI 10.1371/journal.pone.0232739